NIH | National Cancer Institute | NCI Wiki  

Error rendering macro 'rw-search'

null

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 4 Next »

How to Complete the Trial Details Section

In the various fields, specify the appropriate information. The following table describes the fields. An asterisk (*) indicates a required field.

Instructions for recording Trial Details

Field LabelDescription/Instructions

Title*

Enter the official name of the protocol provided by the study principal investigator or sponsor.
For example: "Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Metastatic Adenocarcinoma of the Prostate"

Trial Type*

Select Non-Interventional.

Non-Interventional Trial Type*

Select one of the following trial types:

  1. Observational. Studies among cancer patients and healthy populations that involve no interventions or alteration of the participants.
  2. Ancillary-Correlative. A trial that is secondary to another trial, or a type of trial that tests for a relationship between a condition and a potential causal factor of the condition.
    • Ancillary. Studies that are stimulated by, but are not a required part of, a main clinical trial/study, and that utilize patient or other resources of the main trial/study to generate information relevant to it. Ancillary studies must be linked to an active clinical research study and should include only patients accrued to that clinical research study. Report only those studies that can be linked to individual patient or participant data.
    • Correlative. Laboratory-based studies using specimens to assess cancer risk, clinical outcomes, response to therapies, etc. Report only those studies that can be linked to individual patient or participant data.

Primary Purpose*

1. Select the primary reason for conducting the trial from the following values.

Unable to render {include} The included page could not be found.

2. If your trial does not fall into one of these categories, select Other, and note the type of trial in the corresponding text box.

The text box is displayed only after you have selected Other.

Study Model Code*

1. Select the primary strategy for subject identification and follow-up. The following list provides valid values.

  • Cohort. Group of individuals, initially defined and composed, with common characteristics (e.g., condition, birth year), who are examined or traced over a given time period
  • Case-control. Group of individuals with specific characteristics (e.g., conditions or exposures) compared to group(s) with different characteristics, but otherwise similar
  • Case-only. Single group of individuals with specific characteristics
  • Case-crossover. Characteristics of case immediately prior to disease onset (sometimes called the hazard period) compared to characteristics of same case at a prior time (i.e., control period)
  • Ecologic or community studies. Geographically defined populations, such as countries or regions within a country, compared on a variety of environmental (e.g., air pollution intensity, hours of sunlight) and/or global measures not reducible to individual level characteristics (e.g., health care system, laws or policies median income, average fat intake, disease rate)
  • Family-based. Studies conducted among family members, such as genetic studies within families or twin studies and studies of family environment
  • Other. Any model not described above

2. If the study model is Other, type a detailed description of the trial’s study model in the text field provided.

The text field is displayed only after you have selected Other.

Time Perspective Code*

1. Select the temporal relationship of observation period to time of subject enrollment. The following list provides valid values.

  • Prospective - Look forward using periodic observations collected predominantly following subject enrollment
  • Retrospective - Look back using observations collected predominantly prior to subject selection and enrollment
  • Cross-sectional - Observations or measurements made at a single point in time, usually at subject enrollment
  • Other - Any time perspective not described above

2. If the time perspective is Other, type a detailed description of the trial’s time perspective in the text field provided.

The text field is displayed only after you have selected Other. The limit is 200 characters; the system counts down the character numbers as you type.

Phase*

Select the phase or stage of the clinical trial as defined by the US FDA, from the drop-down list. The following list provides valid values.

Select N/A for observational and ancillary-correlative trials.

When you specify trial data in CTRP, the system requires you to specify the phase of investigation, as defined by the US FDA for trials involving investigational new drugs. The following table provides a definition of each phase and maps the ClinicalTrials.gov values to the CTRP values:
CTRP Phase ValueClinicalTrials.gov Phase ValueDefinition
Early Phase IEarly Phase 1 (Formerly listed as "Phase 0")Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies). See FDA guidance on exploratory IND studies for more information.
IPhase 1Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
I/IIPhase 1/Phase 2Trials that are a combination of phases 1 and 2.
IIPhase 2Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
II/IIIPhase 2/Phase 3Trials that are a combination of phases 2 and 3.
IIIPhase 3Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
IVPhase 4Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
NAN/ATrials without phases (for example, studies of devices or behavioral interventions).

Is this a Pilot?

Select Yes or No from the drop-down list to indicate whether the trial you are registering is a pilot trial.

Site Principal Investigator*

Click Look Up Person and search for the principal investigator. See Looking Up Registered Persons.

  • No labels